Celcuity Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELC research report →
Companywww.celcuity.com
Celcuity Inc. , a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
- CEO
- Brian F. Sullivan
- IPO
- 2017
- Employees
- 87
- HQ
- Minneapolis, MN, US
Price Chart
Valuation
- Market Cap
- $6.84B
- P/E
- -39.63
- P/S
- 0.00
- P/B
- 142.80
- EV/EBITDA
- -41.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -244.61%
- ROIC
- -49.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-177,042,000 · -58.39%
- EPS
- $-3.78 · -33.57%
- Op Income
- $-172,192,000
- FCF YoY
- -83.39%
Performance & Tape
- 52W High
- $151.02
- 52W Low
- $10.26
- 50D MA
- $120.40
- 200D MA
- $91.37
- Beta
- 0.09
- Avg Volume
- 888.28K
Get TickerSpark's AI analysis on CELC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | Buller Richard E | other | 1,029 |
| May 19, 26 | Buller Richard E | other | 1,029 |
| May 4, 26 | Dalvey David | sell | 25,000 |
| May 4, 26 | Buller Richard E | other | 9,000 |
| May 4, 26 | Buller Richard E | sell | 1,289 |
| May 4, 26 | Buller Richard E | sell | 550 |
| May 4, 26 | Buller Richard E | sell | 1,670 |
| May 4, 26 | Buller Richard E | sell | 2,301 |
| May 4, 26 | Buller Richard E | sell | 2,825 |
| May 4, 26 | Buller Richard E | sell | 365 |
Our CELC Coverage
We haven't published any research on CELC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CELC Report →